Iveda Solutions Inc. logo

Iveda Solutions Inc. (IVDA)

Market Closed
15 Oct, 08:00 PM
NASDAQ (CM) NASDAQ (CM)
$
0. 23
+0
+0.6019%
Pre Market
$
0. 25
+0.02 +8.1197%
3.15M Market Cap
- P/E Ratio
- Div Yield
138,375 Volume
-0.04 Eps
$ 0.23
Previous Close
Add Transaction
Day Range
0.23 0.24
Year Range
0.21 1.52
Want to track IVDA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
2 International Microcaps for Your Watchlist

2 International Microcaps for Your Watchlist

SSII and IVDA have sales predominantly in India and Taiwan, respectively.

Zacks | 4 days ago
IVDA Stock Declines 43.4% as Q2 Loss Widens, Revenues Fall Y/Y

IVDA Stock Declines 43.4% as Q2 Loss Widens, Revenues Fall Y/Y

Iveda Solutions' Q2 revenues drop 48% y/y and its net loss widens 41%, while stronger contract margins lift the gross margin to 55%.

Zacks | 1 month ago
Iveda Stock Looks Cheap, But Is It Worth the Risk Right Now?

Iveda Stock Looks Cheap, But Is It Worth the Risk Right Now?

IVDA's AI smart-city portfolio, open platform and Taiwan contracts support growth, but concentration and uneven revenues keep the stock a high-risk bet.

Zacks | 3 months ago
Iveda Launches Prompt-Driven AI Surveillance Technology

Iveda Launches Prompt-Driven AI Surveillance Technology

IVDA unveils real-time zero-shot AI detection that enables users to create custom surveillance models from simple text prompts without training or data labeling.

Zacks | 4 months ago
Iveda Q1 Loss Narrows Y/Y, Revenues Rise as Taiwan Sales Drive Growth

Iveda Q1 Loss Narrows Y/Y, Revenues Rise as Taiwan Sales Drive Growth

IVDA posts higher first-quarter revenues and a narrower y/y loss as strong Taiwan government contract sales boost margins and improve results.

Zacks | 4 months ago
Iveda Reports Narrower Y/Y Loss in 2025 Despite Revenue Decline

Iveda Reports Narrower Y/Y Loss in 2025 Despite Revenue Decline

IVDA posts a narrower y/y loss in 2025 despite a revenue drop on cost cuts and improved margins. Its ongoing reliance on Taiwan operations remains a key risk.

Zacks | 6 months ago
Zacks Initiates Coverage of IVDA With Neutral Recommendation

Zacks Initiates Coverage of IVDA With Neutral Recommendation

Discover why Zacks, the first on Wall Street to initiate coverage, rates IVDA as "Neutral." Explore how Iveda Solutions is extending its cash runway and improving margins amid ongoing profitability and concentration risks.

Zacks | 7 months ago